Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.

Pasquale MoneAngela LombardiJessica GambardellaAntonella PansiniGaetano MacinaMaria MorganteSalvatore FrulloneJoseph H Taube

Published in: Diabetes care (2022)

This study is the first to show significant beneficial effects of the SGLT2 inhibitor empagliflozin on cognitive and physical impairment in frail older adults with diabetes and HFpEF.

Keyphrases

physical activity
community dwelling
cognitive impairment
type diabetes
cardiovascular disease
mental health
glycemic control
skeletal muscle
insulin resistance
weight loss